Takeda: Excellent Pipeline Kaizen - 6 Drugs, $20 Billion Annually

2025-09-24 17:40:34 ET

Introduction

Takeda ( TAK ) is currently a unique biopharma case that may lead to opportunities for investors. While the company is facing significant valuation issues, particularly after the costly Shire acquisition, the company has performed deft kaizen to improve their pipeline. In fact, Takeda has quietly developed six phase 3 therapies that have the opportunity to disrupt competition or provide a first-mover advantage in key, profitable niches. Takeda expects to earn up to $20 billion in revenues upon approval and commercialization. These peak sales estimates, included in the following analysis are taken from Takeda’s estimations provided at their JPM 2025 presentation . However, these are lofty figures so I will determine whether they may end up true or not. The key is to analyze each molecule individually, particularly as Takeda has been extremely selective in choosing this pipeline. Let’s take a look....

Read the full article on Seeking Alpha

For further details see: